In addition, with the prediction that GH therapy will enhance adenotonsillar hypertrophy in PWS, the patients should be questioned for shortness of breath, snoring and sleep apnea and, if necessary, should be evaluated via polysomnography on the 3rd and 6th months after treatment. The gene discussed is GH1; the disease is Sleep apnea.